

# Qing-Lin Peng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3003782/publications.pdf>

Version: 2024-02-01

44  
papers

1,148  
citations

489802

18  
h-index

466096

32  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1349  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. <i>Rheumatology</i> , 2022, 61, 2672-2681.	0.9	12
2	Necroptosis contributes to myofiber death in idiopathic inflammatory myopathies. <i>Arthritis and Rheumatology</i> , 2022, , .	2.9	11
3	The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients. <i>Frontiers in Medicine</i> , 2022, 9, 771784.	1.2	1
4	Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. <i>Rheumatology</i> , 2022, 62, 397-406.	0.9	8
5	Resistin Expression Is Associated With Interstitial Lung Disease in Dermatomyositis. <i>Frontiers in Medicine</i> , 2022, 9, 903887.	1.2	2
6	Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, 425.	0.8	6
7	Serum levels of anti-transcriptional intermediary factor 1- $\beta$ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152011.	1.6	4
8	Expansion of circulating peripheral TIGIT <sup>+</sup> CD226 <sup>+</sup> CD4 T cells with enhanced effector functions in dermatomyositis. <i>Arthritis Research and Therapy</i> , 2021, 23, 15.	1.6	14
9	Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 628128.	1.8	10
10	The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 635654.	1.6	16
11	Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 741-748.	1.6	16
12	miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy. <i>Frontiers in Immunology</i> , 2021, 12, 780237.	2.2	1
13	A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. <i>Clinical and Experimental Immunology</i> , 2020, 199, 314-325.	1.1	27
14	Aberrant expansion of circulating CD4 <sup>+</sup> CXCR5 <sup>+</sup> CCR7 <sup>lo</sup> PD1 <sup>hi</sup> Tfh precursor cells in idiopathic inflammatory myopathy. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 397-405.	0.9	8
15	Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	1.4	8
16	Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-217096.	0.5	10
17	Identification of a novel autoantibody against heat shock factor 1 in idiopathic inflammatory myopathy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1191-1200.	0.4	1
18	The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2019, 21, 131.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	14
20	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 2171-2179.	1.0	41
21	Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. <i>Clinical Rheumatology</i> , 2019, 38, 1655-1663.	1.0	32
22	FRI0308â€¦HIGH LEVEL OF SERUM NEOPTERIN IS ASSOCIATED WITH RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE AND REDUCED SURVIVAL IN DERMATOMYOSITIS. , 2019, , .		0
23	OP0181â€¦MOLECULAR CHARACTERIZATION AND STRATIFICATION OF IDIOPATHIC INFLAMMATORY MYOPATHIES: ON THE BASIS OF SKELETAL MUSCLE TRANSCRIPTOME STUDY. , 2019, , .		0
24	Differential Clinical Associations of Antiâ€œNuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2018, 70, 1288-1297.	2.9	20
25	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2018, 45, 835-840.	1.0	23
26	The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. <i>Clinical Rheumatology</i> , 2018, 37, 1573-1580.	1.0	10
27	Targeted capture sequencing identifies novel genetic variations in Chinese patients with idiopathic inflammatory myopathies. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1619-1626.	0.9	6
28	Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. <i>Modern Rheumatology</i> , 2017, 27, 122-129.	0.9	30
29	Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. <i>Journal of Rheumatology</i> , 2017, 44, 1051-1057.	1.0	123
30	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. <i>Scientific Reports</i> , 2017, 7, 188.	1.6	65
31	Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 252-260.	0.9	6
32	Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 259.	1.6	134
33	Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. <i>Scientific Reports</i> , 2016, 6, 32818.	1.6	22
34	Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. <i>Scientific Reports</i> , 2016, 6, 27479.	1.6	29
35	Anti-HMGR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	2.5	105
36	The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2016, 35, 2715-2721.	1.0	19

#	ARTICLE	IF	CITATIONS
37	HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. PLoS ONE, 2016, 11, e0161436.	1.1	21
38	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. PLoS ONE, 2015, 10, e0141616.	1.1	66
39	Discovery of new biomarkers of idiopathic inflammatory myopathy. Clinica Chimica Acta, 2015, 444, 117-125.	0.5	22
40	Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue. Journal of Rheumatology, 2015, 42, 979-987.	1.0	31
41	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clinical Rheumatology, 2015, 34, 2097-2103.	1.0	47
42	B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomarkers in Medicine, 2014, 8, 395-403.	0.6	13
43	FRI0524...Elevated HMGB1 and Decreased Micrnas Expression in Polymyositis: Potential Contributions to Muscle Inflammation and Degeneration. Annals of the Rheumatic Diseases, 2014, 73, 577.1-577.	0.5	0
44	Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyostis: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e94128.	1.1	96